Company Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-05 pm EDT			5-day change	1st Jan Change
34.18 ^CNY	+3.20%		+6.65%	-17.12%

Apr. 29	Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 25	Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006	CI

Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.

Number of employees: 1,167

CNY in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	455	100.0 %	705	100.0 %	+54.86%

CNY in Million	2022	Weight	2023	Weight	Delta
China 97.1 %	446	97.9 %	684	97.1 %	+53.49%
Overseas 2.9 %	9	2.1 %	21	2.9 %	+119.96%

Managers	Title	Age	Since
Sheng Feng Li CEO	Chief Executive Officer	65	03-07-27
Xian Hong Zhan DFI	Director of Finance/CFO	46	19-04-18
Xiao Yun Wu CHM	Chairman	43	10-12-31
Xian Ming Huang CTO	Chief Tech/Sci/R&D Officer	59	18-02-28
Cui Hua Liu BRD	Director/Board Member	59	22-05-19
Dan Yu BRD	Director/Board Member	43	-
Jin Chen Yu BRD	Director/Board Member	66	12-12-31
Cai Bao PRN	Corporate Officer/Principal	38	10-06-30

Members of the board	Title	Age	Since
Cheuk Kin Law BRD	Director/Board Member	61	20-09-09
Sheng Feng Li CEO	Chief Executive Officer	65	03-07-27
Jin Chen Yu BRD	Director/Board Member	66	12-12-31
Xian Ming Huang CTO	Chief Tech/Sci/R&D Officer	59	18-02-28
Dan Yu BRD	Director/Board Member	43	-
Jian Ping Wang BRD	Director/Board Member	70	19-03-04
Xiao Yun Wu CHM	Chairman	43	10-12-31
Cai Bao PRN	Corporate Officer/Principal	38	10-06-30
Wei Jia Tang BRD	Director/Board Member	44	-
Yi Fan Chen BRD	Director/Board Member	-	16-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	414,080,000	86,112,800 ( 20.80 %)	0	20.80 %

Name	Equities	%	Valuation
Liang Yu Yi 44.31 %	181,310,272	44.31 %	898 M ¥
Sheng Feng Li 13.12 %	53,695,061	13.12 %	266 M ¥
Guangzhou Qiaoxing Investment Partnership LP 5.663 %	23,173,326	5.663 %	115 M ¥
Guangzhou Zhongke Yuechuang Incubator Investment Mgmt Co. Ltd. 5.210 %	21,320,002	5.210 %	106 M ¥
Jifu Venture Investment Co. Ltd. 4.991 %	20,423,412	4.991 %	101 M ¥
Xian Zhong Yi 3.910 %	16,000,000	3.910 %	79 M ¥
Guangzhou Fanwan Lake Investment Partnership LP 1.814 %	7,424,586	1.814 %	37 M ¥
Zheng Qing Dong 1.115 %	4,560,931	1.115 %	23 M ¥
Hefei Qixing Equity Investment Partnership LP 0.6348 %	2,597,404	0.6348 %	13 M ¥
Orient Securities Asset Management Co. Ltd. 0.5760 %	2,356,912	0.5760 %	12 M ¥

Bio-Thera Solutions, Ltd.

5/F, Building A6 11 Kaiyuan Avenue

510530, Guangzhou

http://www.bio-thera.com

address Bio-Thera Solutions, Ltd.(688177)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

33.12 CNY

Average target price

54 CNY

Spread / Average Target

+63.04%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BIO-THERA SOLUTIONS, LTD.	-19.69%	1.9B
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+5.21%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-6.45%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
VIKING THERAPEUTICS, INC.	+313.59%	8.49B

Bio Therapeutic Drugs